Nuclear medicine diagnostic tools for early detection of myocardial damage in treated breast cancer patients
Journal Title: OncoReview - Year 2014, Vol 4, Issue 3
Abstract
The most severe side effect in treated patients with breast cancer is treatment-induced cardiotoxicity, leading to chronic heart failure or CAD, and worsening the patient’s quality of life. The early detection and medical protection is needed to prevent it. The aim of the study was to detect early signs of cardiotoxicity.[b]Material and methods[/b]: 148 breast cancer patients were included in the study: 64 after combined treatment (chemo- and radiotherapy), 56 patients after radiotherapy, 28 patients after chemotherapy. We performed myocardial scintigraphy (GSPECT-CT), EchoCG, ProBNP measurement.[b]Results[/b]: The analysis of the results present early signs of cardiotoxicity in 46% of investigated patients. Exclusion criteria were: patients with cardiac symptoms, pathologic ECG and LVEF. EchoCG results indicated normal systolic function in all (n = 120) patients (mean LVEF 64%), in 79 (66%) patients – normal diastolic function, in 41 (34%) patients diastolic dysfunction was found. Myocardial scintigraphy: normal systolic function was found in all patients (mean LVEF 68%), no segmental dysfunction, diastolic dysfunction had 47 (32%) patients. Hypoperfused myocardial segments were found in 39 (26%) patients. Normal myocardial perfusion had 125 (84%) patients. ProBNP: normal ProBNP values were measured in 64 patients, increased values – in 7 (9%) patients.[b]Conclusion[/b]: The results indicated earlier detection of signs of cardiotoxicity in comparison to the routine diagnostic methods. Applying myocardial GSPECT-CT, we can detect early signs of myocardial damage before positive results from routine tests for cardiotoxicity and before severe morphologic myocardial damage.
Authors and Affiliations
Antonia Tzonevska, Krasimir Tzvetkov, Mariana Atanasova, Anna Chakarova
Keywords
Related Articles
- EP ID EP67758
- DOI -
- Views 186
- Downloads 0
Tumor lysis syndrome
Tumor lysis syndrome is a life-threatening oncological emergency occurring in response to chemotherapy or spontaneously as a result of massive and rapid breakdown of malignant cells. The release of their contents into ci...
Dylematy w leczeniu raka nerki - pazopanib
Postęp w leczeniu systemowym przerzutowego raka nerki związany jest z rejestracją nowych leków. Przyniosło to poprawę wyników leczenia, ale zmusza również do dokonywania wyboru leku. Decyzja ta jest szczególnie istotna w...
Rola eksemestanu w leczeniu raka piersi
Leczenie hormonalne jest jedną z podstawowych opcji terapeutycznych w leczeniu raka piersi, zarówno miejscowo zaawansowanego, jak i przerzutowego. Standardem od wielu lat pozostaje tamoksyfen, jednak wyniki nowych badań...
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Purpose: Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metas...
Meeting the human. What can I get out of it?
Recently patients representatives are more often invited to oncological congresses. They would like to draw attention of the medical society to other than medical problems of people with cancer. Doctors should remember h...